ASH 2014: Phase III VALOR trial shows that vosaroxin versus placebo improves overall survival in first-relapsed or refractory acute myeloid leukaemia - 101271

Spotlight
Video

ASH 2014: Phase III VALOR trial shows that vosaroxin versus placebo improves overall survival in first-relapsed or refractory acute myeloid leukaemia

EMJ has 458 videos Subscribe Here

Loading........
Description: At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses the phase III double-blind randomized controlled multinational VALOR study, which evaluated vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first-relapsed or refractory acute myeloid leukaemia.
Shared By : EMJ
Posted on : 12/09/14
Added : 3 years ago